Milind Deshpande - Net Worth and Insider Trading
Milind Deshpande Net Worth
The estimated net worth of Milind Deshpande is at least $16,900 dollars as of 2024-04-27. Milind Deshpande is the CEO of Achillion Pharmaceuticals Inc and owns about 2,500 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $16,900. Details can be seen in Milind Deshpande's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Milind Deshpande has not made any transactions after 2016-12-02 and currently still holds the listed stock(s).
Transaction Summary of Milind Deshpande
Milind Deshpande Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Milind Deshpande owns 2 companies in total, including Spero Therapeutics Inc (SPRO) , and Achillion Pharmaceuticals Inc (ACHN) .
Click here to see the complete history of Milind Deshpande’s form 4 insider trades.
Insider Ownership Summary of Milind Deshpande
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SPRO | Spero Therapeutics Inc | 2017-11-01 | director |
| ACHN | Achillion Pharmaceuticals Inc | 2018-02-09 | director & Chief Executive Officer |
Milind Deshpande Latest Holdings Summary
Milind Deshpande currently owns a total of 1 stock. Milind Deshpande owns 2,500 shares of Achillion Pharmaceuticals Inc (ACHN) as of December 2, 2016, with a value of $16,900.
Latest Holdings of Milind Deshpande
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACHN | Achillion Pharmaceuticals Inc | 2016-12-02 | 2,500 | 6.76 | 16,900 |
Holding Weightings of Milind Deshpande
Milind Deshpande Form 4 Trading Tracker
According to the SEC Form 4 filings, Milind Deshpande has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the acquisition of 2,500 shares on December 2, 2016, which cost Milind Deshpande around $10,150.
Insider Trading History of Milind Deshpande
- 1
Milind Deshpande Trading Performance
GuruFocus tracks the stock performance after each of Milind Deshpande's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Milind Deshpande is -1.72%. GuruFocus also compares Milind Deshpande's trading performance to market benchmark return within the same time period. The performance of stocks bought by Milind Deshpande within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Milind Deshpande's insider trading performs compared to the benchmark.
Performance of Milind Deshpande
Average Return
-25.62%
Outperforming Transactions
0%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.72 | -1.72 | 23.89 | -25.62 | -15.67 | 15.03 |
| Relative Return to S&P 500(%) | -0.42 | -10.39 | 12.62 | -46.16 | -27.92 | 2.62 |
Milind Deshpande Ownership Network
Ownership Network List of Milind Deshpande
Ownership Network Relation of Milind Deshpande
Milind Deshpande Owned Company Details
What does Spero Therapeutics Inc do?
Who are the key executives at Spero Therapeutics Inc?
Milind Deshpande is the director of Spero Therapeutics Inc. Other key executives at Spero Therapeutics Inc include Chief Financial Officer Sath Shukla , Chief Medical Officer Kamal Hamed , and Chief Development Officer Timothy Keutzer .
Spero Therapeutics Inc (SPRO) Insider Trades Summary
Over the past 18 months, Milind Deshpande made no insider transaction in Spero Therapeutics Inc (SPRO). Other recent insider transactions involving Spero Therapeutics Inc (SPRO) include a net sale of 91,515 shares made by Sath Shukla , a net sale of 85,121 shares made by Ankit Mahadevia , and a net sale of 36,219 shares made by Timothy Keutzer .
In summary, during the past 3 months, insiders sold 229,741 shares of Spero Therapeutics Inc (SPRO) in total and bought 0 shares, with a net sale of 229,741 shares. During the past 18 months, 316,580 shares of Spero Therapeutics Inc (SPRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 316,580 shares.
Spero Therapeutics Inc (SPRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Spero Therapeutics Inc Insider Transactions
Milind Deshpande Mailing Address
Above is the net worth, insider trading, and ownership report for Milind Deshpande. You might contact Milind Deshpande via mailing address: Achillion Pharmaceuticals, 300 George Street, New Haven Ct 06511.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
